GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Beneish M-Score

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Beneish M-Score : -3.06 (As of May. 10, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Inovio Pharmaceuticals's Beneish M-Score or its related term are showing as below:

INO' s Beneish M-Score Range Over the Past 10 Years
Min: -4.44   Med: -2.95   Max: 2.62
Current: -3.06

During the past 13 years, the highest Beneish M-Score of Inovio Pharmaceuticals was 2.62. The lowest was -4.44. And the median was -2.95.


Inovio Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Inovio Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Beneish M-Score Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 2.62 -4.44 0.29 -3.06

Inovio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.91 0.46 -3.50 -3.06

Competitive Comparison of Inovio Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Inovio Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Beneish M-Score falls into.



Inovio Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Inovio Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.5271+0.528 * 1+0.404 * 0.4501+0.892 * 0.0811+0.115 * 1.2013
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 6.5075+4.679 * -0.012583-0.327 * 0.8664
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.41 Mil.
Revenue was 0.103 + 0.388 + 0.226 + 0.115 = $0.83 Mil.
Gross Profit was 0.103 + 0.388 + 0.226 + 0.115 = $0.83 Mil.
Total Current Assets was $153.11 Mil.
Total Assets was $170.95 Mil.
Property, Plant and Equipment(Net PPE) was $14.45 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.50 Mil.
Selling, General, & Admin. Expense(SGA) was $47.58 Mil.
Total Current Liabilities was $42.57 Mil.
Long-Term Debt & Capital Lease Obligation was $11.03 Mil.
Net Income was -25.004 + -33.93 + -35.535 + -40.649 = $-135.12 Mil.
Non Operating Income was 0.853 + -10.515 + -0.348 + 1.409 = $-8.60 Mil.
Cash Flow from Operations was -26.276 + -29.111 + -32.315 + -36.664 = $-124.37 Mil.
Total Receivables was $11.74 Mil.
Revenue was 0.125 + 9.154 + 0.784 + 0.199 = $10.26 Mil.
Gross Profit was 0.125 + 9.154 + 0.784 + 0.199 = $10.26 Mil.
Total Current Assets was $315.24 Mil.
Total Assets was $348.53 Mil.
Property, Plant and Equipment(Net PPE) was $17.96 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.50 Mil.
Selling, General, & Admin. Expense(SGA) was $90.19 Mil.
Total Current Liabilities was $96.87 Mil.
Long-Term Debt & Capital Lease Obligation was $29.27 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.405 / 0.832) / (11.738 / 10.262)
=2.890625 / 1.143832
=2.5271

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10.262 / 10.262) / (0.832 / 0.832)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (153.113 + 14.453) / 170.951) / (1 - (315.243 + 17.956) / 348.533)
=0.019801 / 0.043996
=0.4501

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.832 / 10.262
=0.0811

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.496 / (5.496 + 17.956)) / (3.503 / (3.503 + 14.453))
=0.234351 / 0.195088
=1.2013

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(47.582 / 0.832) / (90.185 / 10.262)
=57.189904 / 8.788248
=6.5075

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11.032 + 42.57) / 170.951) / ((29.27 + 96.868) / 348.533)
=0.313552 / 0.361911
=0.8664

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-135.118 - -8.601 - -124.366) / 170.951
=-0.012583

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Inovio Pharmaceuticals has a M-score of -3.06 suggests that the company is unlikely to be a manipulator.


Inovio Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422